Business Context and Reporting Period
Company: Edgewise Therapeutics, Inc. (EWTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Edgewise is a late-stage clinical biopharmaceutical company focused on developing precision medicines for severe muscle diseases. The company utilizes a proprietary drug discovery platform to target key muscle proteins. Its lead programs include sevasemten for Duchenne and Becker muscular dystrophy, EDG-7500 for hypertrophic cardiomyopathy (HCM), and EDG-15400 for heart failure with preserved ejection fraction (HFpEF). The company has no products approved for commercial sale and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(167.8) | $(133.8) |
| Research & Development Expenses | $151.4 | $127.0 |
| General & Administrative Expenses | $40.0 | $31.9 |
| Interest Income | $23.6 | $25.0 |
| Cash, Cash Equivalents & Marketable Securities | $530.1 | $470.2 |
| Accumulated Deficit | $(546.4) | $(378.6) |
| Net Cash Used in Operating Activities | $(143.8) | $(109.0) |
Note: The company does not report profit margins or debt levels as it has no revenue and no long-term debt obligations.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $34.0 million (25.4%) year-over-year, driven primarily by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $24.4 million. Key drivers included:
- Sevasemten: Increased costs for the MESA open-label extension trial and the GRAND CANYON pivotal cohort enrollment.
- EDG-15400: New program expenses of $7.6 million as the candidate advanced into Phase 1 trials.
- EDG-7500: Increased costs for the CIRRUS-HCM Phase 2 trial (Parts B, C, and D).
- Internal Costs: A $16.7 million increase in personnel-related costs and stock-based compensation due to headcount growth.
- Capital Raise: In April 2025, the company closed an underwritten registered direct offering, raising net proceeds of $187.1 million.
- Interest Income Decline: Interest income decreased by $1.4 million due to lower average treasury yields, partially offset by higher average securities balances.
Guidance, Outlook, and Risks
Outlook and Liquidity:
- Management expects to continue incurring significant losses for the foreseeable future.
- As of December 31, 2025, the company held $530.1 million in cash and marketable securities, which management believes is sufficient to fund operations for at least the next 12 months.
- The company anticipates R&D expenses will increase substantially as it advances sevasemten, EDG-7500, and EDG-15400 through later-stage clinical trials.
Clinical Progress Highlights:
- Sevasemten (Becker): Completed enrollment in the GRAND CANYON pivotal cohort. Positive topline data from the CANYON Phase 2 trial showed significant reduction in CK biomarkers and stabilization of functional measures (NSAA).
- Sevasemten (Duchenne): Encouraging observations from LYNX and FOX Phase 2 trials regarding functional measures and biomarker reduction.
- EDG-7500 (HCM): Completed enrollment in Part D of the CIRRUS-HCM Phase 2 trial. Data showed significant reductions in LVOT gradients and NT-proBNP without meaningful reduction in Left Ventricular Ejection Fraction (LVEF).
Key Risks and Contingencies:
- Capital Requirements: The company will require substantial additional capital to complete development and commercialization. Failure to raise capital could force delays or elimination of programs.
- Clinical Trial Outcomes: Early positive results do not guarantee success in pivotal trials. The FDA may require additional testing or disagree with data interpretations.
- Regulatory Uncertainty: Changes in FDA policies, leadership, or the overturning of the Chevron doctrine could impact approval timelines and standards.
- Competition: Significant competition exists in Duchenne (e.g., Sarepta, PTC Therapeutics) and HCM (e.g., BMS, Cytokinetics) markets.
- Third-Party Dependence: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing introduces supply chain and execution risks.
Investor Verification Checklist
- Cash Runway: Verify the $530.1 million cash balance and the 12-month runway projection against current burn rates.
- Sevasemten Pivotal Data: Monitor upcoming topline data releases for the GRAND CANYON (Becker) and LYNX/FOX (Duchenne) trials to confirm statistical significance on primary endpoints.
- EDG-7500 Phase 3 Design: Review the design and timeline for Phase 3 trials in HCM, expected to be informed by CIRRUS-HCM Part D data.
- Capital Markets Access: Assess the status of the Leerink ATM program (up to $175 million available) and potential for future equity dilution.
- Regulatory Feedback: Track any new FDA guidance or feedback regarding the NDA filing strategy for sevasemten in Becker and Duchenne.